BRAF and neoplasm: Problems related to tumor clonality and the presence of different mutations in the BRAF gene may be solved by NGS, which is a robust technology that could, in the future, function as a substitute for other techniques (qPCR, Seq, pyrosequencing) because of its superior sensitivity and ability to comprehensively assess mutation composition in tumor tissue in a single analysis.